BACE1 and Alzheimer disease: Another research group focused on the design and synthesis of a series of twelve new benzimidazole/1,3,5-triazine-2,4-diamine hybrids (38, Figure 16) as potential multitarget agents for AD, evaluating their potential as inhibitors of AChE, BuChE and BACE-1 [56].